Acute Myeloid Leukemia Clinical Trial
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.
Patients must have a Karnofsky (adult) Performance Status of at least 70%.
Patients must have adequate organ function
Female patients who are pregnant or breast-feeding
Active viral, bacterial or fungal infection
Patient seropositive for Human Immunodeficiency Virus (HIV-I /II); Human T-Cell Lymphotrophic Virus (HTLV -I /II)
Presence of leukemia in the Central Nervous System (CNS).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Miami Florida, 33176, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.